Walleye Trading’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-1,400
Closed -$179K 4410
2025
Q2
$179K Buy
+1,400
New +$145K ﹤0.01% 3299
2025
Q1
Sell
-1,500
Closed -$131K 4093
2024
Q4
$131K Buy
+1,500
New +$137K ﹤0.01% 3429
2024
Q3
Sell
-900
Closed -$97K 4130
2024
Q2
$97K Sell
900
-1,000
-53% -$100K ﹤0.01% 3383
2024
Q1
$180K Sell
1,900
-2,800
-60% -$240K ﹤0.01% 3483
2023
Q4
$434K Buy
+4,700
New +$305K ﹤0.01% 3199
2023
Q2
Sell
-8,100
Closed -$364K 4718
2023
Q1
$364K Buy
8,100
+3,100
+62% +$140K ﹤0.01% 3066
2022
Q4
$219K Buy
+5,000
New +$240K ﹤0.01% 3500
2021
Q1
Sell
-4,300
Closed -$482K 4820
2020
Q4
$482K Buy
+4,300
New +$453K ﹤0.01% 2694
2020
Q2
Sell
-32,600
Closed -$1.91M 4242
2020
Q1
$1.91M Buy
32,600
+600
+2% +$38.6K 0.01% 865
2019
Q4
$2.56M Buy
+32,000
New +$2.4M 0.02% 1019
2019
Q3
Sell
-900
Closed -$85K 4036
2019
Q2
$85K Hold
900
﹤0.01% 3369
2019
Q1
$72K Buy
+900
New +$66.5K ﹤0.01% 3605
2018
Q4
Sell
-8,900
Closed -$695K 4656
2018
Q3
$695K Buy
8,900
+4,000
+82% +$278K ﹤0.01% 2506
2018
Q2
$311K Buy
4,900
+4,200
+600% +$334K ﹤0.01% 3258
2018
Q1
$64K Buy
+700
New +$60.3K ﹤0.01% 4069

Other funds holding BPMC

Walleye Trading's BPMC Position: Q1 2025 in Review

Walleye Trading sold out of Blueprint Medicines (BPMC) in Q1 2025, closing a stake of 1,731 shares — an estimated $151K sold.

Walleye Trading first reported a position in BPMC in Q2 2016 and held it in 10 quarters. The position peaked at $2.03M in Q4 2023. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.

  • Walleye Trading reported no remaining Blueprint Medicines position as of Q1 2025 after selling out during the quarter.
  • Walleye Trading sold 1,731 Blueprint Medicines shares in Q1 2025, an estimated $151K.
  • Walleye Trading first reported a position in Blueprint Medicines in Q2 2016 and held it in 10 quarters.
  • Walleye Trading's Blueprint Medicines position peaked at $2.03M in Q4 2023.
  • 352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.

Based on Walleye Trading's 13F filing for Q1 2025, filed 14 May 2025.